We analyzed more than 13 000 single tumor cells from biopsies taken before treatment (n = 37), after treatment (n = 22) and metastases (n = 3) from 37 HER2‐positive (HER2+) breast cancer patients. This evidence concerns the gene ERBB2 and breast carcinoma.